cagrisema cagrilintide semaglutide phase 3 obesity Three new REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes CagriSema: Strong Obesity Data, but

Semaglutide promotes weight loss by: Appetite suppression: By activating GLP-1 receptors in the brain, Semaglutide helps to reduce hunger and increase feelings of fullness, leading to decreased calorie intake

Unleash a radiant, even-toned complexion with our Gluta-C Kojic Plus+ Whitening Face & Neck Cream

"AstraZeneca teams with Bristol-Myers on diabetes drugs"

Mental health : Increases the risk of anxiety and depression, while lowering self-esteem and life satisfaction

These medications raise GLP-1 to normal levels and part of the impact is quieting the noise. As a result, people taking GLP-1 drugs are finding that all sorts of daily experiences that used to trigger a compulsion to eat or think about food no longer have this effect, says Thomas Wadden, PhD, a psychology and psychiatry professor at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia